Effects of Sparsentan After Maximized Angiotensin Receptor Blocker (ARB) Treatment in Patients With IgA Nephropathy (IgAN) in the PROTECT Trial
Practical Considerations for the Use of Sparsentan in the Treatment of Patients with IgAN in Clinical Practice
62nd European Renal Association (ERA) Congress 2025
June 6 - 7, 2025
Austria
Travere and National Kidney Foundation Collaboration
Implications of Proteinuria Remission on Estimated Glomerular Filtration Rate Trajectory in Patients With IgA Nephropathy in PROTECT
American Nephrology Nurses Association (ANNA) National Symposium 2025
May 1 - 4, 2025
OR
Patient-Reported Outcomes in Rare Kidney Disease Clinical Trials: Sparsentan Versus Irbesartan
A New Dawn for IgA Nephropathy – Redefining What is Possible with Sparsentan Presented by Travere and ISN
March 11, 2025
Virtual
World Congress of Nephrology (WCN) 2025
February 6 - 9, 2025
India
ASN Update
ASN 2024 Spotlight: New Treatment Targets in IgA Nephropathy
PROTECT Subgroup Analysis: Sparsentan Provides Clinical Benefits vs Irbesartan in Patients With IgA Nephropathy With Proteinuria Above and Below 1 g/g
Concomitant Sparsentan (SPAR) and Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) in Patients with IgA Nephropathy (IgAN) in the PROTECT Open-Label Extension (OLE)